Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention

Journal of Interventional Cardiology

Volumn 17, Issue 5, 2004, Pages 307-313

  Díez, Jose G ^a,b   Cheong, Benjamin Y C ^a   O'Meallie, Lawrence P ^a   Alt, Eckhard U ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; DEVICE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; DRUG MONITORING; ENOXAPARIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WHOLE BLOOD COAGULATION TIME;

EID: 7244251497     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2004.04030.x     Document Type: Article

References (23)

1. Braunwald E, Antman EM, Beasley JW, et al. American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. J Am Coll Cardiol 2002;40:1366-1374.
2. ENOX™ Test Card package insert. Available at: http://enoxtest.com/ pdfs/enoxpackageinsert.pdf.
3. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first." J Invasive Cardiol 2000;12 (Suppl. A):1A-5A.
4. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol 2000;12 (Suppl. E):E14-E18.
5. Kereiakes DJ, Grines C, Fry E, et al. NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-278.
6. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
7. Moliterno DJ, Hermiller JB, Kereiakes DJ, et al. For the ELECT Investigators. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: Results of the evaluating enoxaparin clotting times (ELECT) study. J Am Coll Cardiol 2003;42:1132-1139.
8. Martin JL, Fry ET, Serano A, et al. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes. The PEPCI study. Eur Heart J 2001;22:14.
9. Heart Disease and Stroke Statistics-2003 Update, American Heart Association. Available at: http://www.americanheart. org/downloadable/heart/ 10590179711482003HDSStatsBook REV7-03.pdf.
10. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-372.
11. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
12. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114(Suppl. 5):489S-510S.
13. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997;337:447-452.
14. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
15. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
16. Ferguson JJ. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: The NICE 3 story. National Investigators Collaborating on Enoxaparin. J Invasive Cardiol 2000;12(Suppl. E):E10-E13.
17. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study. J Am Coll Cardiol 2003;41:20-25.
18. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-1950.
19. Aslam MS, Sundberg S, Sabri MN, et al. Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 2002;57:187-190.
20. Díez JG, Lievano MJ, Olaya CA, et al. Enoxaparin anticoagulation for percutaneous coronary interventions: A pilot safety study. Circulation 1999;100:I-188.
21. Nguyen V, O'Meallie L, Tenaglia A, et al. Low molecular weight heparin versus unfractionated heparin in percutaneous coronary intervention: The Tulane experience. Catheter Cardiovasc Interv 2002;56:124.
22. The SYNERGY Executive Committee. Superior Yield of the New Strategy of Enoxaparin, Revascularization and G1Ycoprotein IIb/IIIa Inhibitors. The SYNERGY trial: Study design and rationale. Am Heart J 2002;143:952-960.
23. Diez JG, Nguyen VD, Cheong BYC, et al. Enoxaparin is safer and more effective than unfractionated heparin in contemporary percutaneous coronary interventions, in preparation. Circulation 2003;108(Suppl IV):IV-569.